BioCentury
ARTICLE | Clinical News

Interleukin-4 fusion with Pseudomonas exotoxin: NBIX began Phase I/II

December 7, 1998 8:00 AM UTC

Neurocrine Biosciences Inc. (NBIX), San Diego, Calif. Product: Interleukin-4 fusion with Pseudomonas exotoxin Indication: Treat brain cancer (glioblastoma and astrocytoma) Status: NBIX began Phase I/I...